JP2004514673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004514673A5 JP2004514673A5 JP2002544415A JP2002544415A JP2004514673A5 JP 2004514673 A5 JP2004514673 A5 JP 2004514673A5 JP 2002544415 A JP2002544415 A JP 2002544415A JP 2002544415 A JP2002544415 A JP 2002544415A JP 2004514673 A5 JP2004514673 A5 JP 2004514673A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- trifluoromethyl
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 cyclic tertiary amine Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- IXHFNEAFAWRVCF-UHFFFAOYSA-N N,2-dimethylpropanamide Chemical compound CNC(=O)C(C)C IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 claims 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- MKQPUZPYZAHOQG-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenoxy)-2-(2-morpholin-4-ylethoxy)pyrimidin-5-yl]propanamide Chemical compound C=1N=C(OCCN2CCOCC2)N=C(OC=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MKQPUZPYZAHOQG-UHFFFAOYSA-N 0.000 claims 1
- WQQLAXNHNONZLX-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenoxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]propanamide Chemical compound C=1N=C(N2CCN(C)CC2)N=C(OC=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WQQLAXNHNONZLX-UHFFFAOYSA-N 0.000 claims 1
- MDIINQXUSJVVSN-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenoxy)-2-methylsulfanylpyrimidin-5-yl]propanamide Chemical compound C=1C=CC=C(C)C=1OC1=NC(SC)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MDIINQXUSJVVSN-UHFFFAOYSA-N 0.000 claims 1
- CEHBBAMHDHCNOA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenoxy)-2-morpholin-4-ylpyrimidin-5-yl]propanamide Chemical compound C=1N=C(N2CCOCC2)N=C(OC=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CEHBBAMHDHCNOA-UHFFFAOYSA-N 0.000 claims 1
- JEAOLVJEETWDHD-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenoxy)-2-piperazin-1-ylpyrimidin-5-yl]propanamide Chemical compound C=1N=C(N2CCNCC2)N=C(OC=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JEAOLVJEETWDHD-UHFFFAOYSA-N 0.000 claims 1
- WYKVONSWOUJLND-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[2-[2-(dimethylamino)ethoxy]-4-(2-methylphenoxy)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=CC=C(C)C=1OC1=NC(OCCN(C)C)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WYKVONSWOUJLND-UHFFFAOYSA-N 0.000 claims 1
- HMBVXCHFZBKNFF-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[2-[2-(dimethylamino)ethoxy]-4-(4-fluorophenoxy)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=C(F)C=CC=1OC1=NC(OCCN(C)C)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HMBVXCHFZBKNFF-UHFFFAOYSA-N 0.000 claims 1
- CTWOMEAGTBRCGV-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[2-[2-(dimethylamino)ethylamino]-4-(2-methylphenoxy)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=CC=C(C)C=1OC1=NC(NCCN(C)C)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CTWOMEAGTBRCGV-UHFFFAOYSA-N 0.000 claims 1
- FLUULSJWDGVHNV-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[2-[3-(dimethylamino)propoxy]-4-(2-methylphenoxy)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=CC=C(C)C=1OC1=NC(OCCCN(C)C)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FLUULSJWDGVHNV-UHFFFAOYSA-N 0.000 claims 1
- LTAPECFHQNBSJR-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[2-[3-(dimethylamino)propoxy]-4-(4-fluorophenoxy)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=C(F)C=CC=1OC1=NC(OCCCN(C)C)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LTAPECFHQNBSJR-UHFFFAOYSA-N 0.000 claims 1
- XGYLAROFDBQJSA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenoxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(C)CC2)N=C(OC=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XGYLAROFDBQJSA-UHFFFAOYSA-N 0.000 claims 1
- AASDAECXVNZWNM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenoxy)-2-[2-(dimethylamino)ethoxy]pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=CC=C(Cl)C=1OC1=NC(OCCN(C)C)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AASDAECXVNZWNM-UHFFFAOYSA-N 0.000 claims 1
- IUVRSNFCPNILPH-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenoxy)-2-methylsulfanylpyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=CC=C(Cl)C=1OC1=NC(SC)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IUVRSNFCPNILPH-UHFFFAOYSA-N 0.000 claims 1
- WKQMQMYALVTXSV-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenoxy)-2-morpholin-4-ylpyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1N=C(N2CCOCC2)N=C(OC=2C(=CC=CC=2)Cl)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WKQMQMYALVTXSV-UHFFFAOYSA-N 0.000 claims 1
- GEJGPKWIPRGMBN-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(4-fluorophenoxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1N=C(N2CCN(C)CC2)N=C(OC=2C=CC(F)=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GEJGPKWIPRGMBN-UHFFFAOYSA-N 0.000 claims 1
- CCJVCXTYIFDQDO-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(4-fluorophenoxy)-2-methylsulfanylpyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1C=C(F)C=CC=1OC1=NC(SC)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CCJVCXTYIFDQDO-UHFFFAOYSA-N 0.000 claims 1
- YOXFTPLQUCBPIX-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(4-fluorophenoxy)-2-piperazin-1-ylpyrimidin-5-yl]-N,2-dimethylpropanamide Chemical compound C=1N=C(N2CCNCC2)N=C(OC=2C=CC(F)=CC=2)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YOXFTPLQUCBPIX-UHFFFAOYSA-N 0.000 claims 1
- PVSVRPXIFWFGJY-UHFFFAOYSA-N 2-[3-[3-[2,2-diphenylethyl-[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]phenyl]acetamide Chemical compound NC(=O)CC1=CC=CC(OCCCN(CC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC=2C=C(C=CC=2)C(F)(F)F)=C1 PVSVRPXIFWFGJY-UHFFFAOYSA-N 0.000 claims 1
- NDXDZSNCQMEXDE-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[2-(dimethylamino)ethoxy]-N-methyl-4-(2-methylphenoxy)pyrimidine-5-carboxamide Chemical compound C=1C=CC=C(C)C=1OC1=NC(OCCN(C)C)=NC=C1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NDXDZSNCQMEXDE-UHFFFAOYSA-N 0.000 claims 1
- CWVPKHZZLZNKNE-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound C=1N=C(N2CCN(C)CC2)N=C(OC=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CWVPKHZZLZNKNE-UHFFFAOYSA-N 0.000 claims 1
- JBGFKOOMNWLABT-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-piperazin-1-ylpyrimidine-5-carboxamide Chemical compound C=1N=C(N2CCNCC2)N=C(OC=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JBGFKOOMNWLABT-UHFFFAOYSA-N 0.000 claims 1
- WANYMOIWTMVWMU-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]methyl-methylazanide Chemical compound C[N-]CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WANYMOIWTMVWMU-UHFFFAOYSA-N 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
Claims (24)
- 一般式I:
R2は、水素、低級アルキル、低級アルコキシ、ハロゲンまたはトリフルオロメチルであり;
R3/R3 ′は、互いに独立して、水素または低級アルキルであり;
R4は、互いに独立して、ハロゲン、トリフルオロメチルまたは低級アルコキシであり;
R5は、水素または低級アルキルであり;
Rは、互いに独立して、水素または低級アルキルであり;
Xは、−C(O)N(R)−または−N(R)C(O)−であり;
Yは、−O−、−S−、−SO2−または−N(R)−であり;
nは、1、2、3または4であり;
mは、0、1または2である〕
で示される化合物、および薬学的に許容されうるその酸付加塩。 - Xが−C(O)N(CH3)−であり、Yが−O−である、請求項1記載の式Iの化合物。
- R1が環状第三級アミンである、請求項2記載の式Iの化合物。
- 2−(4−メチル−ピペラジン−1−イル)−4−o−トリルオキシ−ピリミジン−5−カルボン酸(3,5−ビス−トリフルオロメチル−ベンジル)−メチル−アミド、
2−ピペラジン−1−イル−4−o−トリルオキシ−ピリミジン−5−カルボン酸(3,5−ビス−トリフルオロメチル−ベンジル)−メチル−アミド、または
4−(2−クロロ−フェノキシ)−2−(4−メチル−ピペラジン−1−イル)−ピリミジン−5−カルボン酸(3,5−ビス−トリフルオロメチル−ベンジル)−メチル−アミド
である、請求項3記載の式Iの化合物。 - R1が−O−(CH2)n−環状第三級アミンである、請求項2記載の式Iの化合物。
- 2−(2−モルホリン−4−イル−エトキシ)−4−o−トリルオキシ−ピリミジン−5−カルボン酸(3,5−ビス−トリフルオロメチル−ベンジル)−メチル−アミドである、請求項5記載の式Iの化合物。
- R1が基−O−(CH2)−NR2である、請求項2記載の式Iの化合物。
- 2−(2−ジメチルアミノ−エトキシ)−4−o−トリルオキシ−ピリミジン−5−カルボン酸(3,5−ビス−トリフルオロメチル−ベンジル)−メチル−アミドである、請求項7記載の化合物。
- Xが−N(CH3)C(O)−であり、Yが−O−である、請求項1記載の式Iの化合物。
- R1が−S−低級アルキルである、請求項9記載の式Iの化合物。
- 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(2−メチルスルファニル−4−o−トリルオキシ−ピリミジン−5−イル)−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(4−フルオロ−フェノキシ)−2−メチルスルファニル−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、または
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(2−クロロ−フェノキシ)−2−メチルスルファニル−ピリミジン−5−イル〕−N−メチル−イソブチルアミド
である請求項9記載の式Iの化合物。 - R1が環状第三級アミンである、請求項9記載の式Iの化合物。
- 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(2−モルホリン−4−イル−4−o−トリルオキシ−ピリミジン−5−イル)−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−〔2−(4−メチル−ピペラジン−1−イル)−4−o−トリルオキシ−ピリミジン−5−イル〕−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−(2−ピペラジン−1−イル−4−o−トリルオキシ−ピリミジン−5−イル)−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(4−フルオロ−フェノキシ)−2−(4−メチル−ピペラジン−1−イル)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(4−フルオロ−フェノキシ)−2−ピペラジン−1−イル−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(2−クロロ−フェノキシ)−2−モルホリン−4−イル−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(2−クロロ−フェノキシ)−2−(4−メチル−ピペラジン−1−イル)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、または
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(2−クロロ−フェノキシ)−2−ピペラジン−1−イル−ピリミジン−5−イル〕−N−メチル−イソブチルアミド
である、請求項12記載の式Iの化合物。 - R1が−N(R)(CH2)nNR2である、請求項9記載の式Iの化合物。
- 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(2−ジメチルアミノ−エチルアミノ)−4−o−トリルオキシ−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、または
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(2−ジメチルアミノ−エチルアミノ)−4−(4−フルオロ−フェノキシ)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド
である、請求項14記載の式Iの化合物。 - R1が−O−(CH2)n−環状第三級アミンである、請求項9記載の式Iの化合物。
- 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−メチル−N−〔2−(2−モルホリン−4−イル−エトキシ)−4−o−トリルオキシ−ピリミジン−5−イル〕−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔4−(2−クロロ−フェノキシ)−2−(2−モルホリン−4−イル−エトキシ)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド
である、請求項16記載の式Iの化合物。 - R1が−O−(CH2)nNR2である、請求項9記載の式Iの化合物。
- 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(2−ジメチルアミノ−エトキシ)−4−o−トリルオキシ−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(3−ジメチルアミノ−プロポキシ)−4−o−トリルオキシ−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(2−ジメチルアミノ−エトキシ)−4−(4−フルオロ−フェノキシ)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(3−ジメチルアミノ−プロポキシ)−4−(4−フルオロ−フェノキシ)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(2−ジメチルアミノ−エトキシ)−4−(2−クロロ−フェノキシ)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド、または
2−(3,5−ビス−トリフルオロメチル−フェニル)−N−〔2−(3−ジメチルアミノ−プロポキシ)−4−(2−クロロ−フェノキシ)−ピリミジン−5−イル〕−N−メチル−イソブチルアミド
である、請求項18記載の式Iの化合物。 - 請求項1〜19のいずれか1項に記載された一つ以上の化合物と、薬学的に許容されうる賦形剤とを含有する医薬。
- NK−1受容体拮抗物質に関連する疾患を処置するための請求項20記載の医薬。
- 請求項1記載の式Iの化合物を製造する方法であって、
(a)式II:
(b)式IV:
(c)式VI:
(d)式VIII:
(e)式Ib1またはIa1:
(f)式I−1:
(g)式I−2:
(h)一個以上の置換基R1、R2、R3、R3 ′、R4またはRを上記に示されている定義内で改変すること、および
所望であれば、得られた化合物を薬学的に許容されうる酸付加塩へと転換することを含む方法。 - 請求項22に記載された方法、または等価な方法によって製造される、請求項1〜19のいずれか1項に記載の化合物。
- NK−1受容体拮抗物質に関連する疾患を処置するための、式Iの化合物を一つ以上含有する医薬の製造のための、請求項1〜19のいずれか1項に記載の化合物の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00125529 | 2000-11-22 | ||
PCT/EP2001/013084 WO2002042280A2 (en) | 2000-11-22 | 2001-11-13 | Pyrimidine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004514673A JP2004514673A (ja) | 2004-05-20 |
JP2004514673A5 true JP2004514673A5 (ja) | 2005-04-21 |
JP3993100B2 JP3993100B2 (ja) | 2007-10-17 |
Family
ID=8170446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002544415A Expired - Fee Related JP3993100B2 (ja) | 2000-11-22 | 2001-11-13 | ピリミジン誘導体 |
Country Status (31)
Country | Link |
---|---|
US (1) | US6787539B2 (ja) |
EP (1) | EP1339698A2 (ja) |
JP (1) | JP3993100B2 (ja) |
KR (1) | KR100571337B1 (ja) |
CN (1) | CN1309710C (ja) |
AR (1) | AR031486A1 (ja) |
AU (2) | AU2792102A (ja) |
BG (1) | BG107840A (ja) |
BR (1) | BR0115480A (ja) |
CA (1) | CA2429570A1 (ja) |
CZ (1) | CZ20031666A3 (ja) |
EC (1) | ECSP034619A (ja) |
GT (1) | GT200100232A (ja) |
HK (1) | HK1078079A1 (ja) |
HR (1) | HRP20030362A2 (ja) |
HU (1) | HUP0303045A3 (ja) |
IL (2) | IL155705A0 (ja) |
JO (1) | JO2307B1 (ja) |
MA (1) | MA26967A1 (ja) |
MX (1) | MXPA03004453A (ja) |
NO (1) | NO324865B1 (ja) |
NZ (1) | NZ525555A (ja) |
PA (1) | PA8533501A1 (ja) |
PE (1) | PE20020760A1 (ja) |
PL (1) | PL366394A1 (ja) |
RU (1) | RU2284997C2 (ja) |
SK (1) | SK7612003A3 (ja) |
UY (1) | UY27034A1 (ja) |
WO (1) | WO2002042280A2 (ja) |
YU (1) | YU39503A (ja) |
ZA (1) | ZA200303517B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20022413A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4 |
WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
JP4613501B2 (ja) | 2004-03-17 | 2011-01-19 | 味の素株式会社 | 5−保護アミノピリミジン化合物の製造方法 |
JP4501015B2 (ja) | 2004-03-17 | 2010-07-14 | 味の素株式会社 | アミノピリミジン化合物の製造方法 |
JP2007534941A (ja) * | 2004-04-22 | 2007-11-29 | ザイゴ コーポレーション | 光学干渉計システムおよび光学干渉計システムを用いる方法 |
WO2005110416A2 (en) * | 2004-05-08 | 2005-11-24 | Neurogen Corporation | 4,5-disubstituted-2-aryl pyrimidines |
CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
DE102005027150A1 (de) * | 2005-03-12 | 2006-09-28 | Bayer Healthcare Ag | Pyrimidincarbonsäure-Derivate und ihre Verwendung |
EP2129381A1 (en) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
KR101032186B1 (ko) * | 2008-12-31 | 2011-05-02 | 엘에스산전 주식회사 | 정격 미세 조정이 가능한 과전류 계전기 |
WO2011053705A1 (en) * | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | Pyrimidine compounds as delta opioid receptor modulators |
JP5770198B2 (ja) * | 2009-10-30 | 2015-08-26 | ヤンセン ファーマシューティカ エヌ.ベー. | オピオイド受容体調節因子としてのフェノキシ置換ピリミジン |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57131771A (en) * | 1981-02-10 | 1982-08-14 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
FR2536071B1 (fr) * | 1982-11-12 | 1986-07-11 | Sanofi Sa | Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant |
DE3752141T2 (de) | 1986-02-24 | 1998-03-26 | Mitsui Petrochemical Ind | Mittel zur behandlung von neuropathie |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
SG52217A1 (en) | 1993-12-29 | 1998-09-28 | Merck Sharp & Dohme | Substituted morpholine derivatives and their use as therapeutic agents |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
CZ20022413A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4 |
-
2000
- 2000-11-13 YU YU39503A patent/YU39503A/sh unknown
-
2001
- 2001-10-15 US US09/977,586 patent/US6787539B2/en not_active Expired - Fee Related
- 2001-11-13 MX MXPA03004453A patent/MXPA03004453A/es active IP Right Grant
- 2001-11-13 CN CNB018191169A patent/CN1309710C/zh not_active Expired - Fee Related
- 2001-11-13 NZ NZ525555A patent/NZ525555A/en unknown
- 2001-11-13 BR BR0115480-0A patent/BR0115480A/pt not_active Application Discontinuation
- 2001-11-13 AU AU2792102A patent/AU2792102A/xx active Pending
- 2001-11-13 SK SK761-2003A patent/SK7612003A3/sk unknown
- 2001-11-13 WO PCT/EP2001/013084 patent/WO2002042280A2/en active IP Right Grant
- 2001-11-13 CZ CZ20031666A patent/CZ20031666A3/cs unknown
- 2001-11-13 AU AU2002227921A patent/AU2002227921B2/en not_active Ceased
- 2001-11-13 IL IL15570501A patent/IL155705A0/xx active IP Right Grant
- 2001-11-13 RU RU2003117481/04A patent/RU2284997C2/ru not_active IP Right Cessation
- 2001-11-13 CA CA002429570A patent/CA2429570A1/en not_active Abandoned
- 2001-11-13 EP EP01989463A patent/EP1339698A2/en not_active Withdrawn
- 2001-11-13 PL PL01366394A patent/PL366394A1/xx not_active Application Discontinuation
- 2001-11-13 JP JP2002544415A patent/JP3993100B2/ja not_active Expired - Fee Related
- 2001-11-13 HU HU0303045A patent/HUP0303045A3/hu unknown
- 2001-11-13 KR KR1020037006777A patent/KR100571337B1/ko not_active IP Right Cessation
- 2001-11-15 JO JO2001188A patent/JO2307B1/en active
- 2001-11-19 PE PE2001001154A patent/PE20020760A1/es not_active Application Discontinuation
- 2001-11-21 AR ARP010105423A patent/AR031486A1/es not_active Application Discontinuation
- 2001-11-21 GT GT200100232A patent/GT200100232A/es unknown
- 2001-11-21 UY UY27034A patent/UY27034A1/es not_active Application Discontinuation
- 2001-11-21 PA PA20018533501A patent/PA8533501A1/es unknown
-
2003
- 2003-05-01 IL IL155705A patent/IL155705A/en not_active IP Right Cessation
- 2003-05-07 ZA ZA200303517A patent/ZA200303517B/en unknown
- 2003-05-08 HR HR20030362A patent/HRP20030362A2/xx not_active Application Discontinuation
- 2003-05-21 NO NO20032291A patent/NO324865B1/no unknown
- 2003-05-21 EC EC2003004619A patent/ECSP034619A/es unknown
- 2003-05-22 BG BG107840A patent/BG107840A/bg unknown
- 2003-05-22 MA MA27173A patent/MA26967A1/fr unknown
-
2005
- 2005-11-11 HK HK05110085A patent/HK1078079A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004290666B2 (en) | N-acylsulfonamide apoptosis promoters | |
JP2004514673A5 (ja) | ||
KR100659428B1 (ko) | Npy 길항제로서의 퀴놀린 유도체 | |
KR101086678B1 (ko) | 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법 | |
US20020188122A1 (en) | Novel compounds | |
CN1213305A (zh) | 新的环烷基取代的咪唑类化合物 | |
RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
JPH0368875B2 (ja) | ||
SK4796A3 (en) | Tri-substituted imidazoles, manufacturing process thereof, pharmaceutical agent containing them and their use | |
JP2002507993A (ja) | 新規な置換イミダゾール化合物 | |
JP2013249316A (ja) | フェニルアミノピリミジン化合物およびその使用 | |
JPS6084282A (ja) | 1−ヘテロアリ−ル−4−〔(2.5−ピロリジンジオン−1−イル)アルキル〕ピペラジン誘導体 | |
JP2004522792A5 (ja) | ||
JP2009504792A5 (ja) | ||
JP4842816B2 (ja) | Cf3−置換ピリミジンの選択的合成 | |
JP2009520811A (ja) | プロテインキナーゼ活性を阻害するアミノピリミジン誘導体、及びその製造方法並びにこれを有効成分として含む医薬組成物 | |
CN1630633A (zh) | 用作缓激肽拮抗剂的在其甲基上具有取代基的n-联苯甲基氨基环烷烃羧酰胺衍生物 | |
JPS6339875A (ja) | ピリミジン誘導体 | |
JP2004532240A5 (ja) | ||
RU2003115426A (ru) | Замещенные производные 2-фениламиноимидазолинфенилкетона в качестве антагонистов ip | |
JP2008509182A5 (ja) | ||
CA2527315A1 (en) | Imidazole derivatives as glutamate receptor antagonists | |
WO2001025218A1 (fr) | Nouveaux derives de quinazoline | |
US20120095015A1 (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
JP2004269469A (ja) | ピリミジン誘導体又はその塩 |